Mark Wallet joined Link Cell Therapies in October 2024 as the Chief Scientific Officer. In his prior role, Mark was VP, Head of Immuno-oncology at Century Therapeutics. In this role, he led pre-clinical development of gene-edited iPSC-derived CAR-NK and CAR-T cell therapies for cancer.
Prior to joining Century, Mark assembled and led the translational science team at Fate Therapeutics where he gained experience in allogenic donor-derived NK cell therapies and iPSC-derived cell therapies for cancer. Through his experience at Fate and Century, Mark has contributed to multiple successful first-in-human INDs including genetically engineered cell therapy products containing up to six genetic modifications.
Before joining the biotech field, Mark was Principal Investigator as a faculty member at the University of Florida in the Department of Pathology, Immunology, and Laboratory Medicine. He holds a Ph.D. degree in Microbiology and Immunology from the University of North Carolina at Chapel Hill.
